American Society of Hirudotherapy

Poeciguamerin

Antistasin-domain dual analgesic + antithrombotic serine protease inhibitor from Poecilobdella manillensis — Wang 2023 explains the painless-bleed phenotype.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 27, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • Poeciguamerin5.5 kDa
Molecular weight (kilodaltons) of Poeciguamerin (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
Preclinical (animal)
Drug vs leech
Purified natural compound
Safety domains
Bleeding

Clinical translation limit

Poeciguamerin's preclinical analgesic + antithrombotic activity in murine models does NOT establish clinical efficacy in humans. No FDA-approved derivative exists; P. manillensis is not the FDA-cleared K040187 medicinal leech species.

Molecular Profile

Category
Proteinase Inhibitor
Evidence tier
Preclinical
Molecular weight
5,500 Da
Source species
Poecilobdella manillensis
Discovered
2023 · Wang C et al.

Biological Targets

  • → leukocyte elastase (primary)
  • → FXIIa
  • → kallikrein

Key Citations

  1. Wang C et al. (2023), Int J Mol Sci · PMID 37446275

External Resources

    Related Proteinase Inhibitor Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.